ORLANDO -- Most adults with type 1 diabetes switching from an insulin pump or multiple daily injections to inhaled insulin (Afrezza) needed to increase their dose of the inhaled product to achieve ...
The updated labeling was supported by modeling data and in vivo results from the Dose Optimization study (see graph) and the INHALE-3 trial that demonstrated improved postprandial glucose outcomes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results